This retrospective study analyzed the efficacy of combined antiplatelet therapy with Argatroban in treating acute ischemic stroke (AIS) and its impact on patients' coagulation and neurological functions. Clinical data of 113 AIS patients admitted between January 2021 and January 2023 were retrospectively analyzed. Patients were divided into control (n = 56) and observation (n = 57) groups based on treatment interventions. The observation group received Argatroban in addition to oral antiplatelet therapy. Compared to the control group, the observation group demonstrated higher clinical efficacy, improved coagulation parameters, reduced stroke severity (measured by NIHSS), enhanced daily living abilities (BI scores), and lowered inflammatory and neural injury markers post-treatment. Adverse reaction incidence was similar between groups. Combining Argatroban with antiplatelet drugs in AIS management showed superior efficacy without increasing adverse effects, suggesting its potential for clinical application.
Keyphrases
- acute ischemic stroke
- end stage renal disease
- antiplatelet therapy
- newly diagnosed
- ejection fraction
- chronic kidney disease
- acute coronary syndrome
- prognostic factors
- peritoneal dialysis
- percutaneous coronary intervention
- clinical trial
- coronary artery disease
- atrial fibrillation
- oxidative stress
- study protocol
- machine learning
- big data
- artificial intelligence
- open label
- data analysis
- replacement therapy
- drug induced